Search

Competing Interests: Conflict of interest B.B.S. has a patent (04/10/14–20140100278): Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia–reperfusion event; M. Urner, L. K. Limbach, I. K. Herrmann, W. J. Stark, B. Beck-Schimmer, applied as Patent Cooperation Treaty (internationally), July 2009, as well as a patent application on bioconjugates of antibodies and functionalized magnetic nanoparticles. B.B.S. and M.S. received grant money from Sedana Medical (Danderyd, Sweden) as collaborators in a large multicentre study not related to this topic. M.S. and B.B.S. received grant money from Roche Diagnostics International (Rotkreuz, Switzerland) for a clinical trial not related to this topic. The authors declare no other conflict of interest.

Background: Liver resection is a well-established treatment for colorectal, neuroendocrine and sarcomatous metastases but remains ill-defined for metastases from other primary sites. This study aimed to analyze the outcomes of hepatic resection for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin and to identify predictors of outcome., Methods: Retrospective analysis of patients undergoing resection for NCNSO metastases in three western centers. Patients were analyzed according to the primary cancer. Outcomes were recurrence and survival., Results: We analyzed 188 patients, divided in: gastrointestinal (59), breast (59) and "others" (70). Median time to recurrence was 15.3 months, while median survival was 52 months. Survival at 1, 3, and 5 years was 78%, 60.4% and 47.8%, respectively. In term of prognostic factors, metastases >35 mm from gastrointestinal tumors were associated with lower survival (p = 0.029) and age>60 years was associated with better survival in breast metastases (p = 0.018)., Conclusions: Liver resection for NCNSO metastases is feasible and results in long-term survival are similar to colorectal metastases. In gastrointestinal metastases, size (<35 mm) could be used to select patients., (Copyright © 2017 Elsevier Inc. All rights reserved.)

A 64-year-old female patient with adenocarcinoma of the head of the pancreas with encasement of the common hepatic artery and portal vein stenosis was reexplored after six cycles of gemcitabine (1000 mg/m2). Prior to surgery, the patient underwent balloon dilation and stenting of the portal vein in addition to successful coil embolisation of the common hepatic artery, proper hepatic artery, and proximal gastro duodenal artery. After embolisation, a pylorus-preserving pancreaticoduodenectomy was performed with resection of the common hepatic artery and portal vein confluens. Pathological examination showed a moderately differentiated pT3N0 (Stage IIa, TNM 7th edition) tumor with negative section margins. We show with this case that in selected cases of periampullary cancer with encasement of the common hepatic artery, it is technically feasible to perform pancreaticoduodenectomy with hepatic artery resection and negative surgical margins. Nevertheless, the oncological benefit of extended arterial resections remains controversial. [ABSTRACT FROM AUTHOR]